MHLW Approves MPS VI Drug Naglzayme
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Anges MG announced that mucopolysaccharidosis VI drug Naglazyme (galsulfase) received manufacturing and marketing approval by Japan's Ministry of Health, Labor and Welfare March 28, three days after it cleared MHLW's drug review panel. The ministry considers Naglazyme the only effective treatment for MPS VI. A severe and progressive genetic disease, MPS is caused by an enzyme deficiency, which leads to progressive organ system dysfunction. Naglazyme has been available in Europe and the U.S and was designated as an orphan drug last June. The NHI price listing will take place in April 18. Anges MG obtained developing and marketing rights in Japan from California-based BioMarin. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.